The first in the country! The group standard for the conversion of high-value biomedical patents is released: providing "patient capital" support for cutting-edge scientific teams (attached with biomedical R&D investment)
Release time:
2022-01-10
On April 19, the first national group standard "Guidelines for the Transformation of Biomedical High-Value Patents Supported by Science and Technology Innovation Finance" was officially released in Shanghai. Zheng Huiqiang, president of the Shanghai Federation of Modern Service Industries, said at the meeting that scientists have had a large number of high-value patents that need to be transformed for a long time, but the lack of long-term R&D funding support has seriously restricted the transformation of scientific and technological achievements and the implementation of applied R&D. It can be seen that it is of great significance to provide sufficient financial guarantees for the "frontier scientist team", improve their scientific research efficiency, and allow them to play a demonstration and leading role without worries.
On April 19, the first national group standard "Guidelines for the Transformation of Biomedical High-Value Patents Supported by Science and Technology Innovation Finance" was officially released in Shanghai. Zheng Huiqiang, president of the Shanghai Federation of Modern Service Industries, said at the meeting that scientists have had a large number of high-value patents that need to be transformed for a long time, but the lack of long-term R&D funding support has seriously restricted the transformation of scientific and technological achievements and the implementation of applied R&D. It can be seen that it is of great significance to provide sufficient financial guarantees for the "frontier scientist team", improve their scientific research efficiency, and allow them to play a demonstration and leading role without worries.
It is worth noting that this group standard combines science and technology innovation finance with the transformation of high-value biomedical patents for the first time . In view of the characteristics of the "frontier scientist team", it proposes "scientist team" + "long cycle", with "predictable, stable and continuous high-value patent" income as a credit enhancement combination innovation plan for risk coverage and risk mitigation. It is groundbreaking to propose that "patient capital" is the leading factor to provide long-term high-value patent transformation financing support for the "frontier scientist team", and proposes the selection criteria for the "frontier scientist team".
recommend News
